View Author
patient myeloma bortezomib dexamethasone treatment study therapy response blood thalidomide lenalidomide trial cancer disease plasma phase combination university survival neuropathy factor result plasma cells grade leukemia hospital analysis month event signi len /dex regimen cycle group incidence myeloma patients ef ficacy progression table neutropenia plasma cell leukemia agent richardson journal marrow response rate high-dose dexamethasone high-dose rearrangement outcome signi ficantly oncol score protein department chemotherapy oncology transplantation hematology randomized british journal baseline novel agents prophylaxi serum panel consensus melphalan effect impairment number induction cell transplantation proteasome chain haematol expression assessment subgroups novel
10 Most Recent Publications
|
Plasma cell leukemia: Consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group
(Article)
Fernández De Larrea, C. Kyle, R. Kumar, S. Mahindra, A. Comenzo, R.L. Palumbo, A. Mazumber, A. Anderson, K.C. Richardson, P.G. Badros, A.Z. Caers, J. Cavo, M. Durie, B.G.M. Leleu, X. Dimopoulos, M.A. Chim, C.S. Schots, R. Noeul, A. Fantl, D. Mellqvist, U.H. Landgren, O. Chanan-Khan, A. Moreau, P. Ludwig, H. Fonseca, R. Merlini, G. Lahuerta, J.J. Bladé, J. Orlowski, R.Z. Shah, J.J. Usmani, S.M. Vesole, D. Hajek, R. San Miguel, J-F. Sezer, O. Sonneveld, P. |
2013-04-01
|
|
How to manage neutropenia in multiple myeloma
(Article)
Palumbo, A. Bladé, J. Spencer, A. Sonneveld, P. San Miguel, J-F. Boccadoro, M. Palladino, C. Davies, F. Dimopoulos, M.A. Dmoszynska, A. Einsele, H. Moreau, P. Sezer, O. |
2012-02-01
|
|
Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: Consensus statement
(Article)
Dimopoulos, M.A. Palumbo, A. Ludwig, H. Mellqvist, U.H. Morgan, G. San Miguel, J-F. Zweegman, S. Sonneveld, P. Attal, M. Beksaç, M. Davies, F. Delforge, M. Einsele, H. Hajek, R. Harousseau, J-L. Da Costa, F.L. |
2011-05-01
|
|
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management
(Article)
Kyle, R. Durie, B.G.M. San Miguel, J-F. Avet-Loiseau, H. Hajek, R. Chen, W. Anderson, K.C. Ludwig, H. Sonneveld, P. Pavlovsky, S. Palumbo, A. Richardson, P.G. Rajkumar, S.V. Barlogie, B. Greipp, P. Vescio, R. Turesson, I. Westin, J. Boccadoro, M. Landgren, O. Bladé, J. Merlini, G. Kröger, N. Einsele, H. Vesole, D. Dimopoulos, M.A. |
2010-04-22
|
|
Current multiple myeloma treatment strategies with novel agents: A European perspective
(Article)
Ludwig, H. Beksac, M. Goldschmidt, H. Harousseau, J-L. Hess, U. Ketterer, N. Kropff, M. Mendeleeva, L. Morgan, G. Palumbo, A. Plesner, T. San Miguel, J-F. Bladé, J. Shpilberg, O. Sondergeld, P. Sonneveld, P. Zweegman, S. Boccadoro, M. Cavenagh, J. Cavo, M. Dimopoulos, M.A. Drach, J. Einsele, H. Facon, T. |
2010-02-05
|
|
The use of bisphosphonates in multiple myeloma: Recommendations of an expert panel on behalf of the European Myeloma Network
(Article)
Terpos, E. Sezer, O. Dimopoulos, M.A. Facon, T. Macro, M. Waage, A. Sonneveld, P. Croucher, P.I. Garcia-Sanz, R. Boccadoro, M. San Miguel, J-F. Ashcroft, J. Blade, J. Cavo, M. Delforge, M. |
2009-10-01
|
|
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: Impact of a dose-modification guideline
(Article)
Richardson, P.G. Sonneveld, P. Bladé, J. Boccadoro, M. Cavenagh, J. Boral, A.L. Esseltine, D-L. Wen, P.Y. Amato, A.A. Anderson, K.C. San Miguel, J-F. Schuster, M.W. Stadtmauer, E.A. Facon, T. Harousseau, J-L. Ben-Yehuda, D. Lonial, S. Goldschmidt, H. Reece, D. |
2009-03-01
|
|
Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: Efficacy and safety in patients with renal function impairment
(Article)
Bladé, J. Sonneveld, P. Harousseau, J-L. Orlowski, R.Z. San Miguel, J-F. Sutherland, H. Hajek, R. Nagler, A. Spencer, A. Robak, T. Cibeira, M.T. Zhuang, S.H. |
2008-12-01
|
|
Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: Results from the APEX study
(Article)
Lee, S.J. Richardson, P.G. Anderson, K.C. Sonneveld, P. Schuster, M.W. Irwin, D. San Miguel, J-F. Crawford, B.T. Massaro, J. Dhawan, R. Gupta, S. |
2008-11-01
|
|
Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma
(Article)
Lonial, S. Richardson, P.G. Anderson, K.C. Harousseau, J-L. San Miguel, J-F. Sonneveld, P. Schuster, M.W. Bladé, J. Cavenagh, J. Rajkumar, S.V. Jakubowiak, A.J. Esseltine, D-L. |
2008-10-01
|
